# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst William Plovanic maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $8 t...
Craig-Hallum analyst Alexander Nowak maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $9 to $12.
2024 Financial Guidance: Based on strong execution and momentum through the first half of 2024, Bioventus is raising financial...
Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.07 by 171...
Canaccord Genuity analyst William Plovanic maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $7 t...